Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 7/1/2015 8:52:46 PM - Followers: 41 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:




Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.




Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
Option Chain for GALT
GALT News: Statement of Changes in Beneficial Ownership (4) 06/02/2015 05:37:25 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 06/01/2015 04:40:29 PM
GALT News: Current Report Filing (8-k) 05/27/2015 08:02:24 AM
GALT News: Confidential Treatment Order (ct Order) 05/26/2015 03:56:01 PM
GALT News: Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders 05/15/2015 08:00:00 AM
#2043   Galectin initiates enrollment in mid-stage trial of GR-MD-02 candeeman 07/01/15 08:52:46 PM
#2042   I've given up being concerned about the share biotech2010 07/01/15 09:45:54 AM
#2041   It's been tough for longs. However, investors, not Adi2 06/27/15 04:23:16 AM
#2040   Yeah, that's right. Be happy. Just IRAHopeful 06/26/15 02:10:14 PM
#2039   dont worry ... be happy ... oldsport 06/26/15 01:28:19 PM
#2038   Any idea what is going on with this jgatsby101 06/26/15 12:57:29 PM
#2037   of course it is... they sold $7 and oldsport 06/16/15 12:38:18 AM
#2036   Institutional ownership up 35.47% Quarter/Quarter candeeman 06/15/15 07:26:37 PM
#2035   Against my better judgement I spent the $25 biotech2010 06/12/15 05:44:18 PM
#2034   Analyst price target is 16.00 within 12 months BlueSkyBreakout 06/12/15 02:22:42 PM
#2033   What's great about this is say this is BlueSkyBreakout 06/11/15 08:42:07 AM
#2032   Was flying all day yesterday and off the Darwinian 06/11/15 02:25:20 AM
#2031   Yeah. I have an opinion. The recent price thefamilyman 06/11/15 12:19:55 AM
#2030   I got that a couple months ago. IRAHopeful 06/10/15 06:51:56 PM
#2029   Anyone have an opinion on this? candeeman 06/10/15 06:35:52 PM
#2028   idk - just saw my acct jump and oldsport 06/10/15 04:10:44 PM
#2027   almost 2 mill. shares today! Any announcements??? IRAHopeful 06/10/15 04:01:14 PM
#2026   wtf is goin on ? oldsport 06/10/15 03:39:48 PM
#2025   Watching Cbdpotential 06/10/15 03:34:28 PM
#2024   I have no idea why the stock is biotech2010 06/10/15 03:23:38 PM
#2023   Silent buying, constant bidding, and insider purchases in BlueSkyBreakout 06/10/15 10:40:31 AM
#2022   The CX Phase 2 trial has been posted Tesla1 06/05/15 01:50:19 PM
#2021   I agree that Czirr is a better presenter thefamilyman 06/05/15 12:16:13 PM
#2020   I listened to it thru the conference feed, biotech2010 06/05/15 07:46:05 AM
#2019   I was going to take your advice and thefamilyman 06/05/15 12:44:42 AM
#2018   Interesting comments made by Czirr during the Q&A biotech2010 06/03/15 09:14:10 AM
#2017   lottery play... oldsport 06/02/15 11:07:12 PM
#2016   ICPT was higher than $430 after their Phase thefamilyman 06/02/15 09:25:12 PM
#2015   Bet he paid more for that party where poonch1ne 06/02/15 09:22:18 PM
#2014   $500 pps ez if this thing nears end oldsport 06/02/15 08:43:44 PM
#2013   10 billion.... That puts the stock price at LordTurkeyBaster 06/02/15 08:21:15 PM
#2012   3000 shares should net you ~$1,000,000 in a thefamilyman 06/02/15 06:54:24 PM
#2011   he owns alot... $10k is nothing... oldsport 06/02/15 06:44:27 PM
#2010   How much does he have to buy to IRAHopeful 06/02/15 04:16:41 PM
#2009   Traber bought some stock, but not a whole poonch1ne 06/01/15 06:13:54 PM
#2008   I kinda agree, i need to average down Darwinian 06/01/15 06:17:59 AM
#2007   Great per clinical studies, great P1 with no DirectionalDriller 06/01/15 12:38:06 AM
#2006   Also, Pat Cox works for John Mauldin who jmh0602 05/31/15 11:42:40 AM
#2005   A little discussion about cancer and Gal-3 by Darwinian 05/31/15 07:04:03 AM
#2004   must be a financial agreement of sort... oldsport 05/28/15 10:24:20 AM
#2003   Before speculating, why not just look at the biotech2010 05/28/15 07:41:47 AM
#2002   new drug application maybe ? oldsport 05/27/15 01:41:47 PM
#2001   You just need to trust Peter Traber. ;-) thefamilyman 05/26/15 10:30:43 PM
#2000   Any guesses as to what the CTO is Darwinian 05/26/15 08:41:42 PM
#1999   Good information on the conference call today. thefamilyman 05/21/15 01:31:43 PM
#1998   Galtw Cbdpotential 05/15/15 09:41:34 PM
#1997   Q. for SH meeting. If the IRAHopeful 05/15/15 04:00:40 PM
#1996   Costs of trials, financing plans, what sort of Adi2 05/15/15 12:37:15 PM
#1995   Anyone got any poignant questions for the SH Darwinian 05/15/15 11:47:43 AM
#1994   They are at phase 2b... Adi2 05/15/15 05:49:00 AM